KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Research & Development (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Research & Development for 8 consecutive years, with $13.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 26.87% year-over-year to $13.9 million, compared with a TTM value of $47.9 million through Dec 2025, up 3.49%, and an annual FY2025 reading of $47.9 million, up 3.49% over the prior year.
  • Research & Development was $13.9 million for Q4 2025 at Esperion Therapeutics, down from $14.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $33.0 million in Q4 2022 and bottomed at $7.2 million in Q2 2025.
  • Average Research & Development over 5 years is $20.3 million, with a median of $19.9 million recorded in 2023.
  • The sharpest move saw Research & Development crashed 57.29% in 2024, then skyrocketed 35.91% in 2025.
  • Year by year, Research & Development stood at $27.6 million in 2021, then rose by 19.62% to $33.0 million in 2022, then crashed by 46.29% to $17.7 million in 2023, then plummeted by 38.13% to $11.0 million in 2024, then increased by 26.87% to $13.9 million in 2025.
  • Business Quant data shows Research & Development for ESPR at $13.9 million in Q4 2025, $14.1 million in Q3 2025, and $7.2 million in Q2 2025.